TW201402132A - 治療非小細胞肺癌之方法 - Google Patents

治療非小細胞肺癌之方法 Download PDF

Info

Publication number
TW201402132A
TW201402132A TW102117597A TW102117597A TW201402132A TW 201402132 A TW201402132 A TW 201402132A TW 102117597 A TW102117597 A TW 102117597A TW 102117597 A TW102117597 A TW 102117597A TW 201402132 A TW201402132 A TW 201402132A
Authority
TW
Taiwan
Prior art keywords
lung cancer
cell lung
human patient
small cell
nucleotides
Prior art date
Application number
TW102117597A
Other languages
English (en)
Chinese (zh)
Inventor
晨 達辛
秀旭 泰斯勒
Original Assignee
泰瓦藥品工業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 泰瓦藥品工業有限公司 filed Critical 泰瓦藥品工業有限公司
Publication of TW201402132A publication Critical patent/TW201402132A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G01N33/5752

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW102117597A 2012-05-18 2013-05-17 治療非小細胞肺癌之方法 TW201402132A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
TW201402132A true TW201402132A (zh) 2014-01-16

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102117597A TW201402132A (zh) 2012-05-18 2013-05-17 治療非小細胞肺癌之方法

Country Status (17)

Country Link
US (1) US20130310440A1 (enExample)
EP (1) EP2849761A1 (enExample)
JP (1) JP2015522542A (enExample)
KR (1) KR20150024843A (enExample)
CN (1) CN104684564A (enExample)
AR (1) AR091090A1 (enExample)
AU (1) AU2013262589A1 (enExample)
BR (1) BR112014028787A2 (enExample)
CA (1) CA2874092A1 (enExample)
EA (1) EA201492148A1 (enExample)
IL (1) IL235459A0 (enExample)
IN (1) IN2014DN10390A (enExample)
PH (1) PH12014502569A1 (enExample)
SG (1) SG11201407649RA (enExample)
TW (1) TW201402132A (enExample)
UY (1) UY34812A (enExample)
WO (1) WO2013173757A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
KR101809623B1 (ko) 2010-05-08 2017-12-15 더 리전트 오브 더 유니버시티 오브 캘리포니아 궤양의 조기 발견을 위한 sem 스캐너 감지 장치, 시스템 및 방법
KR20140038388A (ko) 2011-03-15 2014-03-28 더 유니버시티 오브 브리티쉬 콜롬비아 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
US10182740B2 (en) 2015-04-24 2019-01-22 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
JP7105767B2 (ja) 2017-02-03 2022-07-25 ブルーイン、バイオメトリクス、リミテッド、ライアビリティー、カンパニー 糖尿病性足部潰瘍に対する感受性の測定
AU2018217187B2 (en) 2017-02-03 2020-01-02 Bruin Biometrics, Llc Measurement of edema
DK3515296T3 (da) 2017-02-03 2023-11-27 Bbi Medical Innovations Llc Måling af vævslevedygtighed
GB2575186B (en) 2017-11-16 2020-06-03 Bruin Biometrics Llc Strategic treatment of pressure ulcer using sub-epidermal moisture values
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
PT3749181T (pt) 2018-02-09 2024-05-15 Bruin Biometrics Llc Deteção de lesões nos tecidos
PT4283799T (pt) 2018-10-11 2025-04-23 Bruin Biometrics Llc Dispositivo com elemento descartável
WO2022169850A1 (en) 2021-02-03 2022-08-11 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
WO2009155381A1 (en) * 2008-06-18 2009-12-23 Abbott Laboratories P/gf-1 companion diagnostic methods and products
AU2012257487A1 (en) * 2011-05-19 2014-01-16 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
KR20150024843A (ko) 2015-03-09
JP2015522542A (ja) 2015-08-06
UY34812A (es) 2013-12-31
SG11201407649RA (en) 2014-12-30
AR091090A1 (es) 2014-12-30
EP2849761A1 (en) 2015-03-25
US20130310440A1 (en) 2013-11-21
WO2013173757A8 (en) 2015-04-30
AU2013262589A1 (en) 2015-01-22
PH12014502569A1 (en) 2015-01-21
BR112014028787A2 (pt) 2017-06-27
EA201492148A1 (ru) 2015-04-30
CA2874092A1 (en) 2013-11-21
IL235459A0 (en) 2014-12-31
IN2014DN10390A (enExample) 2015-08-14
WO2013173757A1 (en) 2013-11-21
CN104684564A (zh) 2015-06-03

Similar Documents

Publication Publication Date Title
TW201402132A (zh) 治療非小細胞肺癌之方法
Rosell et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
Gatzemeier et al. Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
CN103958681A (zh) 治疗非小细胞肺癌的方法
Song et al. Phase I trial of selenium plus chemotherapy in gynecologic cancers
KR20180050426A (ko) 치료제의 약물 전달 및 유효성 향상 방법
KR20150131312A (ko) 마이크로rna 및 egfr-tki 억제제를 이용한 조합 암 치료
KR20200014298A (ko) Her2 양성 암의 치료
Gauler et al. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
CN107750165A (zh) 借助塞里班土单抗的组合治疗
McCleary-Wheeler et al. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer
CN105008394A (zh) 治疗结肠直肠癌的方法
TW201130830A (en) Combined treatment of pancreatic cancer with gemcitabine and masitinib
Powell et al. Phase II study of topotecan and bevacizumab in advanced, refractory non–small-cell lung cancer
GB2559162A (en) Compound for use in medicine
WO2012106379A1 (en) Sensitization of cancer cells to treatment
US20170136053A1 (en) Novel pharmaceutical composition and uses thereof
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
Jia et al. Phase 1 dose-escalation study of apatinib and irinotecan in esophageal squamous cell carcinoma patients
Roviello et al. A phase Ib open-label study to assess the safety and tolerability of everolimus in combination with eribulin in triple-negative breast cancers
WO2015171973A9 (en) Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitory compound based on chemosensitive status
US20230338347A1 (en) New Use of Inhibitors of the Notch Signalling Pathway
WO2016179702A1 (en) Acridinone compositions for treating head and neck cancers and methods of prognosing head and neck cancers
Stroes Precision oncology in esophagogastric cancer
Katoen Combining EGFR inhibitors with chemo-and radiotherapy in lung cancer treatment